TY  - JOUR

T1  - Pertuzumab for the Neoadjuvant Treatment of Early-Stage HER2-Positive Breast Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.

JO  - PharmacoEconomics

UR  - http://eprints.whiterose.ac.uk/119850/

PY  - 2018/01/01

AU  - Squires H

AU  - Pandor A

AU  - Thokala P

AU  - Stevens JW

AU  - Kaltenthaler E

AU  - Clowes M

AU  - Coleman R

AU  - Wyld L

ED  - 

DO  - DOI: 10.1007/s40273-017-0556-7

PB  - Adis

VL  - 36

IS  - 1

SP  - 29

EP  - 38

Y2  - 2024/10/19

ER  -